Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
View ORCID ProfileGillian S. Dite, View ORCID ProfileNicholas M. Murphy, View ORCID ProfileRichard Allman
doi: https://doi.org/10.1101/2021.03.09.21253237
Gillian S. Dite
1Genetic Technologies Ltd., Fitzroy, Victoria, Australia
Nicholas M. Murphy
1Genetic Technologies Ltd., Fitzroy, Victoria, Australia
Richard Allman
1Genetic Technologies Ltd., Fitzroy, Victoria, Australia

Article usage
Posted March 28, 2021.
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
Gillian S. Dite, Nicholas M. Murphy, Richard Allman
medRxiv 2021.03.09.21253237; doi: https://doi.org/10.1101/2021.03.09.21253237
Subject Area
Subject Areas
- Addiction Medicine (239)
- Allergy and Immunology (521)
- Anesthesia (124)
- Cardiovascular Medicine (1418)
- Dermatology (158)
- Emergency Medicine (291)
- Epidemiology (10288)
- Gastroenterology (527)
- Genetic and Genomic Medicine (2625)
- Geriatric Medicine (254)
- Health Economics (496)
- Health Informatics (1729)
- Health Policy (789)
- Hematology (266)
- HIV/AIDS (564)
- Medical Education (273)
- Medical Ethics (83)
- Nephrology (288)
- Neurology (2456)
- Nursing (144)
- Nutrition (377)
- Oncology (1320)
- Ophthalmology (400)
- Orthopedics (146)
- Otolaryngology (235)
- Pain Medicine (168)
- Palliative Medicine (51)
- Pathology (342)
- Pediatrics (778)
- Primary Care Research (296)
- Public and Global Health (4999)
- Radiology and Imaging (893)
- Respiratory Medicine (681)
- Rheumatology (309)
- Sports Medicine (244)
- Surgery (297)
- Toxicology (45)
- Transplantation (140)
- Urology (108)